This is the first book to bring together the latest developments in this area. With full colour throughout, each chapter focuses on clinical differentiation and pathophysiology and provides key laboratory and clinical observations. In addition, there is a brief summary of current treatment options.
Author(s): Stephen Jolles
Edition: 1
Publisher: Informa Healthcare
Year: 2002
Language: English
Pages: 148
Book Cover......Page 1
Half-title......Page 2
Title......Page 3
Copyright......Page 4
Contents......Page 6
Contributors......Page 7
Preface......Page 9
Immunoglobulins in the immune system......Page 10
B cell receptor and soluble antibodies......Page 11
Intravenous immunoglobulins —mechanisms of action......Page 14
Suppression of antibody production......Page 15
Neutralization of autoantibodies......Page 16
Interference with antibody-dependent cellular cytotoxicity......Page 18
Restoration of a disturbed Th1/Th2 cytokine balance......Page 20
Modulation of cellular proliferation and apoptosis......Page 22
Effect on glucocorticoid receptor sensitivity......Page 23
References......Page 24
Introduction......Page 28
Results of a controlled study......Page 29
How IVIg exerts its action: studies on repeated muscle biopsies and on post-IVIg sera......Page 32
References......Page 36
Chronic urticaria and chronic ‘idiopathic’ urticaria......Page 38
The late-phase reaction......Page 39
The cutaneous mast cell......Page 40
Histamine-releasing factor......Page 41
Histamine-releasing activity and histamine-releasing autoantibodies......Page 42
Chronic urticaria—three disease subsets......Page 43
Treatment of chronic urticaria......Page 44
Intravenous immunoglobulin......Page 45
Discussion......Page 48
References......Page 51
Evidence in the literature......Page 56
Summary......Page 59
References......Page 62
Epidemiology......Page 65
Clinical features......Page 66
Laboratory findings......Page 69
Bacterial superantigens......Page 70
Treatment with IVIg......Page 71
Mechanism of action of IVIg......Page 73
Treatment for unresponsive Kawasaki disease......Page 74
Long-term sequelae......Page 75
References......Page 77
Introduction......Page 80
Pathogenesis......Page 83
Supportive treatment......Page 84
Intravenous immunoglobulins......Page 85
References......Page 90
Introduction......Page 94
Physician’s checklist prior to high dose IVIg......Page 95
Scleromyxoedema......Page 96
Pyoderma gangrenosum......Page 98
Systemic sclerosis......Page 99
Pretibial myxoedema......Page 101
Psoriasis......Page 102
Discussion......Page 103
References......Page 104
Introduction......Page 107
Pemphigus vulgaris......Page 108
Pemphigus foliaceus......Page 111
Bullous pemphigoid......Page 114
Cicatricial pemphigoid (mucous membrane pemphigoid)......Page 116
Epidermolysis bullosa acquisita......Page 117
Linear IgA bullous disease......Page 119
Side-effects of IVIg therapy......Page 120
Mechanisms of action and autoantibody titers......Page 121
Conclusion......Page 122
References......Page 123
Introduction......Page 128
Pharmacology......Page 132
Virological safety......Page 133
Tolerability......Page 136
References......Page 140
Index......Page 143
